Plus Therapeutics analysis shows cost savings

An analysis by Plus Therapeutics, to be presented at ISPOR, indicates that its CNSide® therapy may reduce healthcare costs associated with leptomeningeal metastases (LM) by 40%. The health economics analysis highlights the significant financial burden of late-stage LM and the potential value of earlier diagnosis and intervention. This finding suggests CNSide® could offer both clinical and economic benefits for patients and the healthcare system.